Among adults with acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA) with planned ...
As a next-generation selective S1P receptor modulator, VELSIPITY® offers the potential for rapid onset of action, and long-lasting clinical remission and mucosal healing through an oral, once-daily ...
Over the past four decades, rare disease drug development has evolved from a scientific aspiration into a central pillar of biopharmaceutical innovation. Regulatory reforms, scientific breakthroughs, ...
Subgroup analysis revealed a pronounced effect among patients receiving MAC. In this cohort, 6-month grade 2-4 GFS was 35.7% with placebo vs 60.7% with ustekinumab (OR 2.78 for failure; 80% CI, 1.19-6 ...
Eli Lilly and Company (NYSE:LLY) Q4 2025 Earnings Call Transcript February 4, 2026 Eli Lilly and Company beats earnings ...
UK: A study published in Nature Medicine has found that external trigeminal nerve stimulation (TNS) is safe in children with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results